ATE554389T1 - Apex als marker für lungenkrebs - Google Patents

Apex als marker für lungenkrebs

Info

Publication number
ATE554389T1
ATE554389T1 AT08716640T AT08716640T ATE554389T1 AT E554389 T1 ATE554389 T1 AT E554389T1 AT 08716640 T AT08716640 T AT 08716640T AT 08716640 T AT08716640 T AT 08716640T AT E554389 T1 ATE554389 T1 AT E554389T1
Authority
AT
Austria
Prior art keywords
lung cancer
apex
marker
assessment
relates
Prior art date
Application number
AT08716640T
Other languages
English (en)
Inventor
Marie-Luise Hagmann
Johann Karl
Julia Kloeckner
Markus Roessler
Michael Tacke
Michael Thierolf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE554389T1 publication Critical patent/ATE554389T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
AT08716640T 2007-03-23 2008-03-19 Apex als marker für lungenkrebs ATE554389T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07006079 2007-03-23
PCT/EP2008/002224 WO2008116592A1 (en) 2007-03-23 2008-03-19 Apex as a marker for lung cancer

Publications (1)

Publication Number Publication Date
ATE554389T1 true ATE554389T1 (de) 2012-05-15

Family

ID=38480598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08716640T ATE554389T1 (de) 2007-03-23 2008-03-19 Apex als marker für lungenkrebs

Country Status (8)

Country Link
US (1) US20110097756A1 (de)
EP (1) EP2130048B1 (de)
JP (1) JP5079023B2 (de)
CN (1) CN101641599A (de)
AT (1) ATE554389T1 (de)
CA (1) CA2681577A1 (de)
ES (1) ES2384125T3 (de)
WO (1) WO2008116592A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120258442A1 (en) 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
AU2005250495A1 (en) 2004-06-04 2005-12-15 Aviaradx, Inc. Identification of tumors
AU2006255282A1 (en) 2005-06-03 2006-12-14 Aviaradx, Inc. Identification of tumors and tissues
CA2742286C (en) * 2008-11-12 2016-08-09 F. Hoffmann-La Roche Ag Pacap as a marker for cancer
ES2493069T3 (es) 2009-05-15 2014-09-11 F. Hoffmann-La Roche Ag CYBP como marcador del cáncer de pulmón
CA2760366A1 (en) 2009-05-29 2010-12-02 F.Hoffmann-La Roche Ag Secernin-1 as a marker for cancer
CN101930004A (zh) * 2009-06-24 2010-12-29 中国科学院上海生命科学研究院 Apex1用作检测肝细胞癌的蛋白质分子标记的应用
KR101251222B1 (ko) * 2010-12-08 2013-04-08 충남대학교산학협력단 ＡＰＥ1/Ｒｅｆ-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트
JP5976691B2 (ja) * 2011-03-11 2016-08-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 慢性閉塞性肺疾患（ｃｏｐｄ）のマーカーとしてのａｐｅｘ１
CN102507951B (zh) * 2011-11-25 2014-11-19 广东药学院 一种联合检测肿瘤标志物的酶联免疫检测试剂盒
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
CA2913334A1 (en) * 2013-05-23 2014-11-27 Iphenotype Llc Method and system for maintaining or improving wellness
CN105891482B (zh) * 2016-03-29 2017-12-19 复旦大学附属中山医院 一种基于生物标志物谱针对中国农村人口肺结节人群的肺癌风险预测模型
CN106018807A (zh) * 2016-05-11 2016-10-12 卢氏实验室公司 一种快速诊断和监控肺癌的免疫层析检测条及其制备方法
CN106053816B (zh) * 2016-08-19 2018-01-05 四川大学华西第二医院 肺癌诊断试剂盒
CN106645722B (zh) * 2016-10-17 2018-09-04 四川大学华西第二医院 一种肺癌筛查试剂盒
CN107860852A (zh) * 2017-11-23 2018-03-30 南宁科城汇信息科技有限公司 一种基于iTRAQ联合LC、MALDI的差异蛋白组学

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919643A (en) * 1996-06-11 1999-07-06 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
AU2713600A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
US20030003454A1 (en) * 2001-03-23 2003-01-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
WO2002076280A2 (en) * 2001-03-23 2002-10-03 Yeda Research And Development Co. Ltd. Methods and kits for determing a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer
JP3691798B2 (ja) * 2002-02-18 2005-09-07 三洋化成工業株式会社 血液中の腫瘍マーカー定量方法
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
WO2005050164A2 (en) * 2003-11-13 2005-06-02 Georgia Tech Research Corporation Detection systems and methods
US7611845B2 (en) * 2004-12-17 2009-11-03 Siemens Healthcare Diagnostics Inc. Serum levels of HER2/neu as an indicator of clinical state and prognosis of prostate cancer
EP2295602B1 (de) * 2005-07-27 2012-07-11 Oncotherapy Science, Inc. Verfahren zur Prognose von Krebsarten
WO2008036465A2 (en) * 2006-09-18 2008-03-27 CMED Technologies Ltd. Office of Walkers Limited A method to assess cancer susceptibility and differential diagnosis of metastases of unknown primary tumors
MX2009009450A (es) * 2007-03-09 2009-12-01 Tripath Imaging Inc Anticuerpos monoclonales para he4 y metodos para su uso.

Also Published As

Publication number Publication date
JP2010521688A (ja) 2010-06-24
CN101641599A (zh) 2010-02-03
US20110097756A1 (en) 2011-04-28
JP5079023B2 (ja) 2012-11-21
EP2130048B1 (de) 2012-04-18
WO2008116592A1 (en) 2008-10-02
CA2681577A1 (en) 2008-10-02
ES2384125T3 (es) 2012-06-29
EP2130048A1 (de) 2009-12-09

Similar Documents

Publication Publication Date Title
ATE554389T1 (de) Apex als marker für lungenkrebs
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
HK1133295A1 (en) Use of protein s100a12 as a marker for colorectal cancer s100a12
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
MX2015016047A (es) Metodo y sistema para mantener o mejorar el bienestar.
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
WO2014020502A3 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
WO2010136163A8 (en) Secernin-1 as a marker for cancer
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
WO2005124356A3 (en) Use of protein cbp2 as a marker for colorectal cancer
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2010000467A8 (en) Asc as a marker for lung cancer
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
MX341181B (es) Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta.
WO2013165969A3 (en) Methods and kits for diagnosing heparin-induced thrombocytopenia
WO2010130839A4 (en) Cybp as a marker of lung cancer
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
SG10201907690TA (en) Device and method for detecting target molecules
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE359516T1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs